BRAIN Biotech Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Aryan Moelker

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate

Apr 19

Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like

Mar 21

Is B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Weighed On By Its Debt Load?

Feb 14

When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven?

Jan 18

How Much Did B.R.A.I.N. Biotechnology Research and Information Network's(ETR:BNN) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 31

Are Institutions Heavily Invested In B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shares?

Dec 10

Should You Investigate B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) At €7.30?

Nov 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Aryan Moelker en comparación con los beneficios de BRAIN Biotech?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-€8m
Sep 30 2023	n/a	n/a	-€8m
Jun 30 2023	n/a	n/a	-€7m
Mar 31 2023	n/a	n/a	-€7m
Dec 31 2022	n/a	n/a	-€7m
Sep 30 2022	n/a	n/a	-€7m
Jun 30 2022	n/a	n/a	-€8m
Mar 31 2022	n/a	n/a	-€8m
Dec 31 2021	n/a	n/a	-€4m
Sep 30 2021	€957k	€420k	-€5m
Jun 30 2021	n/a	n/a	-€6m
Mar 31 2021	n/a	n/a	-€6m
Dec 31 2020	n/a	n/a	-€11m
Sep 30 2020	€885k	€280k	-€10m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Aryan es razonable en comparación con empresas de tamaño similar en el mercado German.

Compensación vs. Ingresos: La compensación de Aryan ha aumentado mientras la empresa no es rentable.

CEO

Aryan Moelker

4.3yrs

Permanencia

€957,000

Compensación

Mr. Adriaan Moelker, also known as Aryan, serves as Director of SolasCure Limited. He has been Chairman of the Management Board and Chief Executive Officer of BRAIN Biotech AG (formerly known as B.R.A.I.N....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Adriaan Moelker	Chairman of the Management Board & CEO	4.3yrs	€957.00k	sin datos
Ulrich Putsch	Co-Founder	no data	sin datos	sin datos
Michael Schneiders	CFO & Member of Management Board	1.6yrs	sin datos	sin datos
Ute Dechert	Vice President of Human Resources & Processes	3.6yrs	sin datos	sin datos
Jurgen Eck	Consultant	4.4yrs	€392.00k	sin datos
Martin Langer	MD & Executive VP	no data	sin datos	sin datos
Alexander Pelzer	VP and Head of Research & Development - Zwingenberg	1.3yrs	sin datos	sin datos
Robbert Hoekstra	Head of Group Finance	1.6yrs	sin datos	sin datos
Paul Scholz	Technical Lead of Genome Editing Development	no data	sin datos	sin datos

2.6yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BNN se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Wiltrud Treffenfeldt	Independent Member of Supervisory Board	3.6yrs	€28.00k	sin datos
Stephen Catling	Independent Member of Supervisory Board	3.6yrs	€31.00k	sin datos
Michael Majerus	Independent Chairman of the Supervisory Board	5.2yrs	€51.00k	sin datos
Anna Eichhorn	Vice Chairwoman of the Supervisory Board	7.2yrs	€53.00k	sin datos
Christine Uekert	Independent Supervisory Board Member	1.2yrs	sin datos	sin datos
Florian Schnabel	Supervisory Board Member	1.2yrs	sin datos	sin datos

3.6yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de BNN se considera experimentada (3.5 años de antigüedad promedio).

BRAIN Biotech Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

BRAIN Biotech AG Announces Executive Changes

BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023

Brain Biotech Ag Announces Resignation of Bernhard Hauer from Supervisory Board, as of May 31, 2022

B.R.A.I.N. Biotechnology Research and Information Network Ag Announces Appointments in Supervisory Board

Recent updates

BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025

BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate

BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable

Now 22% undervalued after recent price drop

BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025

Consensus estimates of losses per share improve by 46%

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings released: €0.12 loss per share (vs €0.12 loss in 1Q 2023)

Is BRAIN Biotech (ETR:BNN) A Risky Investment?

Consensus EPS estimates fall by 68%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.2% to €11.23

BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024

Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022)

Forecast to breakeven in 2025

BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024

New minor risk - Market cap size

Second quarter 2023 earnings released: €0.10 loss per share (vs €0.073 loss in 2Q 2022)

BRAIN Biotech AG to Report Q1, 2024 Results on Feb 28, 2024

BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.

First quarter 2023 earnings released: €0.12 loss per share (vs €0.11 loss in 1Q 2022)

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 30%

Consensus EPS estimates upgraded to €0.17 loss

BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023

BRAIN Biotech AG Announces Executive Changes

Forecast to breakeven in 2025

BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023

Price target decreased to €12.91

Price target increased to €17.50

Forecast to breakeven in 2025

La Cultura Verde Ltd. acquired LA Schmitt from BRAIN Biotech AG (XTRA:BNN).

Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

No longer forecast to breakeven

Brain Biotech Ag Announces Resignation of Bernhard Hauer from Supervisory Board, as of May 31, 2022

Brain Biotech AG Announces Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas, BRAIN-Engineered-Cas

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

No longer forecast to breakeven

Third quarter 2021 earnings released: €0.10 loss per share (vs €0.096 loss in 3Q 2020)

Price target increased to €16.22

No longer forecast to breakeven

Consensus EPS estimates fall to -€0.37

Second quarter 2021 earnings released: EPS €0.10 (vs €0.14 loss in 2Q 2020)

BRAIN Biotech AG (XTRA:BNN) acquired additional 16.7% stake in Biocatalysts Limited from two minority shareholders for £3.9 million.

BRAIN Biotech AG Successfully Completes the First Development Phase for A Novel Genome Editing Tool Based on A Non-Cas9 Nuclease

Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like

First quarter 2021 earnings released: €0.19 loss per share (vs €0.13 loss in 1Q 2020)

B.R.A.I.N. Biotechnology Research and Information Network AG to Report First Half, 2021 Results on May 28, 2021

New 90-day high: €9.58

Is B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Weighed On By Its Debt Load?

Earnings beat expectations, revenue disappoints

Earnings beat expectations, revenue disappoints

When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven?

Full year 2020 earnings released: €0.52 loss per share

Roquette, BRAIN AG, and Brain Group Company AnalytiCon Discovery Successfully Completes the R&D Phase for the Development of Brazzein

B.R.A.I.N. Biotechnology Research and Information Network AG (XTRA:BNN) acquired Biosun Biochemicals Inc.

New 90-day high: €9.08

How Much Did B.R.A.I.N. Biotechnology Research and Information Network's(ETR:BNN) Shareholders Earn From Share Price Movements Over The Last Three Years?

Are Institutions Heavily Invested In B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shares?

New 90-day high: €8.60

Should You Investigate B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) At €7.30?

New 90-day low: €6.92

B.R.A.I.N. Biotechnology Research and Information Network Ag Announces Appointments in Supervisory Board

Price target lowered to €12.77

New 90-day low: €7.62